

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5317479/publications.pdf>

Version: 2024-02-01

32  
papers

1,684  
citations

430442

18  
h-index

454577

30  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1679  
citing authors

#	ARTICLE	IF	CITATIONS
1	Urinary L-FABP is a promising prognostic biomarker of ACLF and mortality in patients with decompensated cirrhosis. <i>Journal of Hepatology</i> , 2022, 76, 107-114.	1.8	21
2	Molecular characterization of chronic liver disease dynamics: From liver fibrosis to acute-on-chronic liver failure. <i>JHEP Reports</i> , 2022, 4, 100482.	2.6	14
3	Patterns of kidney dysfunction in acute-on-chronic liver failure: Relationship with kidney and patients'™ outcome. <i>Hepatology Communications</i> , 2022, 6, 2121-2131.	2.0	8
4	Alterations in Gut Microbiome in Cirrhosis as Assessed by Quantitative Metagenomics: Relationship With Acute-on-Chronic Liver Failure and Prognosis. <i>Gastroenterology</i> , 2021, 160, 206-218.e13.	0.6	89
5	PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 74, 1097-1108.	1.8	149
6	Monitoring Renal Function and Therapy of Hepatorenal Syndrome Patients with Cirrhosis. <i>Clinics in Liver Disease</i> , 2021, 25, 441-460.	1.0	2
7	Reply. <i>Gastroenterology</i> , 2021, 160, 2206.	0.6	0
8	Hyperkalemia influences the outcome of patients with cirrhosis with acute decompensation (AD) and acute-on-chronic liver failure (ACLF). <i>Digestive and Liver Disease</i> , 2021, 53, 738-745.	0.4	5
9	Sequential changes in urinary biomarker levels in patients with cirrhosis and severe hepatorenal syndrome. <i>Liver International</i> , 2021, 41, 2729-2732.	1.9	6
10	Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4885.	1.0	5
11	Lack of evidence for a continuum between hepatorenal syndrome and acute tubular necrosis. <i>Journal of Hepatology</i> , 2020, 72, 581-582.	1.8	5
12	Are We Ready to Evaluate Adrenal Function in Patients With Decompensated Cirrhosis and Acute-on-Chronic Liver Failure?. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1040-1042.	2.4	1
13	The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. <i>Journal of Hepatology</i> , 2020, 73, 842-854.	1.8	282
14	Psychological Burden of Hepatic Encephalopathy on Patients and Caregivers. <i>Clinical and Translational Gastroenterology</i> , 2020, 11, e00159.	1.3	32
15	Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. <i>Journal of Hepatology</i> , 2020, 72, 1132-1139.	1.8	43
16	Reply to: "Midodrine and albumin in decompensated cirrhosis: Down but not out". <i>Journal of Hepatology</i> , 2019, 70, 812.	1.8	0
17	Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury in Cirrhosis: A Prospective Study. <i>Hepatology</i> , 2019, 70, 319-333.	3.6	114
18	Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. <i>Liver International</i> , 2019, 39, 1246-1255.	1.9	64

#	ARTICLE	IF	CITATIONS
19	New Strategies for the Management of Decompensated Cirrhosis: Long-Term Albumin Administration for Everyone?. <i>Hepatology</i> , 2019, 69, 2289-2291.	3.6	2
20	An Unusual Cause of Acute Severe Hepatitis. <i>Gastroenterology</i> , 2019, 156, e3-e4.	0.6	6
21	Association Between Grade of Acute on Chronic Liver Failure and Response to Terlipressin and Albumin in Patients With Hepatorenal Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1792-1800.e3.	2.4	127
22	Actualización en la insuficiencia hepática aguda sobre crónica. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 43-53.	0.2	11
23	Hepatorenal syndrome in the era of acute kidney injury. <i>Liver International</i> , 2018, 38, 1891-1901.	1.9	42
24	Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. <i>Journal of Hepatology</i> , 2018, 69, 1250-1259.	1.8	152
25	Adipocyte Fatty-Acid Binding Protein is Overexpressed in Cirrhosis and Correlates with Clinical Outcomes. <i>Scientific Reports</i> , 2017, 7, 1829.	1.6	30
26	Validation of a Staging System for Acute Kidney Injury in Patients With Cirrhosis and Association With Acute-on-Chronic Liver Failure. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 438-445.e5.	2.4	125
27	Urine Monocyte Chemoattractant Protein-1 Is an Independent Predictive Factor of Hospital Readmission and Survival in Cirrhosis. <i>PLoS ONE</i> , 2016, 11, e0157371.	1.1	20
28	Management of uninfected and infected ascites in cirrhosis. <i>Liver International</i> , 2016, 36, 109-115.	1.9	43
29	Plasma copeptin as biomarker of disease progression and prognosis in cirrhosis. <i>Journal of Hepatology</i> , 2016, 65, 914-920.	1.8	35
30	Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis. <i>Scientific Reports</i> , 2016, 6, 32341.	1.6	101
31	Analysis of a Urinary Biomarker Panel for Clinical Outcomes Assessment in Cirrhosis. <i>PLoS ONE</i> , 2015, 10, e0128145.	1.1	97
32	Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis: A case-control study. <i>Journal of Hepatology</i> , 2015, 63, 593-600.	1.8	53